From bad to worse: Prognostic factors in pancreatic cancer

Annals of Surgical Oncology

Volumn 11, Issue 2, 2004, Pages 117-118

  Lowy, Andrew M ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; K RAS PROTEIN; PROTEIN; PROTEIN P53; PROTEIN P97; TUMOR MARKER; UNCLASSIFIED DRUG; VALOSIN CONTAINING PROTEIN; BIOLOGICAL MARKER; CDC48 PROTEIN; CELL CYCLE PROTEIN;

APOPTOSIS; CANCER CELL; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; DISEASE COURSE; DISEASE MARKER; EDITORIAL; HUMAN; LYMPH NODE METASTASIS; ONCOGENE K RAS; PANCREAS CANCER; PANCREAS RESECTION; POSTOPERATIVE COMPLICATION; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SURVIVAL RATE; METABOLISM; NOTE; PANCREAS TUMOR;

BIOLOGICAL MARKERS; CELL CYCLE PROTEINS; HUMANS; LYMPHATIC METASTASIS; PANCREATIC NEOPLASMS; PROGNOSIS;

EID: 2342655746     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1245/ASO.2004.12.930     Document Type: Editorial

References (5)

1. Yamamoto S, Tomita Y, Hoshida Y, et al. Increased expression of valosin-containing protein (p97) is associated with lymph node metastasis and prognosis of pancreatic ductal adenocarcinoma. Ann Surg Oncol 2004;11:165-72.
2. Dong M, Nio Y, Yamasawa K, et al. p53 alteration is not an independent prognostic indicator, but affects the efficacy of adjuvant chemotherapy in human pancreatic cancer. J Surg Oncol 2003;82:111-20.
3. Gansauge S, Gansauge F, Ramadani M, et al. Overexpression of cyclin D1 in human pancreatic carcinoma is associated with poor prognosis. Cancer Res 1997;57:1634-7.
4. Castells A, Puig P, Mora J, et al. K-ras mutations in DNA extracted from the plasma of patients with pancreatic carcinoma: diagnostic utility and prognostic significance. J Clin Oncol 1999;17:578-84.
5. Conlon KC, Limstra DS, Brennan MF. Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Ann Surg 1996;223:273-9.